GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Samjin Pharmaceutical Co Ltd (XKRX:005500) » Definitions » EBIT

Samjin Pharmaceutical Co (XKRX:005500) EBIT : ₩25,226 Mil (TTM As of Jun. 2024)


View and export this data going back to 1988. Start your Free Trial

What is Samjin Pharmaceutical Co EBIT?

Samjin Pharmaceutical Co's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2024 was ₩7,762 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was ₩25,226 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Samjin Pharmaceutical Co's annualized ROC % for the quarter that ended in Jun. 2024 was 6.58%. Samjin Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 10.75%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Samjin Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 7.49%.


Samjin Pharmaceutical Co EBIT Historical Data

The historical data trend for Samjin Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Samjin Pharmaceutical Co EBIT Chart

Samjin Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21,895.78 32,871.38 35,053.16 26,989.49 19,982.61

Samjin Pharmaceutical Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,953.76 5,159.73 6,866.37 5,437.87 7,762.09

Competitive Comparison of Samjin Pharmaceutical Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Samjin Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Samjin Pharmaceutical Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Samjin Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Samjin Pharmaceutical Co's EV-to-EBIT falls into.



Samjin Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩25,226 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Samjin Pharmaceutical Co  (XKRX:005500) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Samjin Pharmaceutical Co's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=31048.372 * ( 1 - 16.03% )/( (387585.309 + 404853.197)/ 2 )
=26071.3179684/396219.253
=6.58 %

where

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=420254.091 - 38490.349 - ( 6522.466 - max(0, 153925.537 - 148103.97+6522.466))
=387585.309

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=438146.508 - 32524.659 - ( 9938.109 - max(0, 154074.002 - 154842.654+9938.109))
=404853.197

Note: The Operating Income data used here is four times the quarterly (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Samjin Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=31048.372/( ( (190258.078 + max(95185.758, 0)) + (189966.309 + max(102292.101, 0)) )/ 2 )
=31048.372/( ( 285443.836 + 292258.41 )/ 2 )
=31048.372/288851.123
=10.75 %

where Working Capital is:

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(55761.893 + 82992.563 + 1495.281) - (38490.349 + 0 + 6573.63)
=95185.758

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(54545.944 + 85641.381 + 2338.891) - (32524.659 + 0 + 7709.456)
=102292.101

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Samjin Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=25226.06/336919.954
=7.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Samjin Pharmaceutical Co EBIT Related Terms

Thank you for viewing the detailed overview of Samjin Pharmaceutical Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Samjin Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
121, Wausan-ro, Mapo-Ku, Seoul, KOR, 121-837
Samjin Pharmaceutical Co Ltd is a part of the healthcare sector in Korea. The company functions as a pharmaceutical product manufacturer addressing severe diseases such as osteoporosis, hepatitis, respiratory and gastrointestinal diseases. Its suite of products includes capsules, syringes, injection medicines, and solvents.

Samjin Pharmaceutical Co Headlines

No Headlines